CareMax (CMAX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

CMAX Stock Forecast


CareMax stock forecast is as follows: an average price target of $2.20 (represents a 1293.90% upside from CMAX’s last price of $0.16) and a rating consensus of 'Hold', based on 2 wall street analysts offering a 1-year stock forecast.

CMAX Price Target


The average price target for CareMax (CMAX) is $2.20 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $2.20 to $2.20. This represents a potential 1293.90% upside from CMAX's last price of $0.16.

CMAX Analyst Ratings


Hold

According to 2 Wall Street analysts, CareMax's rating consensus is 'Hold'. The analyst rating breakdown for CMAX stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 2 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

CareMax Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 14, 2024AJ RiceUBS$2.20$2.152.33%1293.90%
Apr 12, 2024Jack SlevinJefferies$3.00$2.884.17%1800.78%
Apr 01, 2024AJ RiceUBS$6.40$4.8232.78%3955.00%
Jan 06, 2023UBS$6.00$3.6166.20%3701.56%

The latest CareMax stock forecast, released on Jul 14, 2024 by AJ Rice from UBS, set a price target of $2.20, which represents a 2.33% increase from the stock price at the time of the forecast ($2.15), and a 1293.90% increase from CMAX last price ($0.16).

CareMax Price Target by Period


1M3M12M
# Anlaysts--3
Avg Price Target--$3.87
Last Closing Price$0.16$0.16$0.16
Upside/Downside-100.00%-100.00%2352.01%

In the current month, the average price target of CareMax stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CareMax's last price of $0.16. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jul 14, 2024UBSNeutralNeutralHold
Apr 12, 2024JefferiesHoldHoldHold
Apr 01, 2024UBSNeutralNeutralHold
Jan 06, 2023UBSBuyBuyHold

CareMax's last stock rating was published by UBS on Jul 14, 2024. The company gave CMAX a "Neutral" rating, the same as its previous rate.

CareMax Financial Forecast


CareMax Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
Revenue------------$151.84M$201.84M$224.44M$172.98M$164.26M$157.67M$172.28M$136.92M$118.31M$104.62M$44.92M
Avg Forecast$331.71M$334.80M$372.20M$344.27M$318.66M$318.03M$349.78M$253.92M$176.78M$178.57M$221.40M$197.24M$189.69M$194.45M$184.41M$175.97M$149.70M$141.05M$136.21M$130.06M$118.36M$108.30M$114.54M
High Forecast$331.71M$334.80M$372.20M$344.27M$318.66M$318.03M$349.78M$253.92M$176.78M$178.57M$221.40M$197.24M$189.78M$194.74M$184.41M$175.97M$149.70M$141.05M$136.21M$130.06M$118.36M$108.30M$114.54M
Low Forecast$331.71M$334.80M$372.20M$344.27M$318.66M$318.03M$349.78M$253.92M$176.78M$178.57M$221.40M$197.24M$189.60M$194.16M$184.41M$175.97M$149.70M$141.05M$136.21M$130.06M$118.36M$108.30M$114.54M
# Analysts11111111111131111111111
Surprise %------------0.80%1.04%1.22%0.98%1.10%1.12%1.26%1.05%1.00%0.97%0.39%

CareMax's average Quarter revenue forecast for Mar 24 based on 1 analysts is $197.24M, with a low forecast of $197.24M, and a high forecast of $197.24M. CMAX's average Quarter revenue forecast represents a 29.90% increase compared to the company's last Quarter revenue of $151.84M (Dec 23).

CareMax EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts11111111111131111111111
EBITDA------------$-476.14M$-110.47M$-38.92M$-4.09M$1.53M$-3.40M$8.55M$-6.03M$10.38M$3.62M$-6.71M
Avg Forecast$-38.56M$-38.92M$-43.27M$-40.02M$-37.05M$-36.97M$-40.66M$-29.52M$-20.55M$-20.76M$-25.74M$-22.93M$-22.05M$-22.61M$-21.44M$-20.46M$-17.40M$-626.10K$-604.60K$-66.33M$-525.39K$-480.75K$-23.97M
High Forecast$-38.56M$-38.92M$-43.27M$-40.02M$-37.05M$-36.97M$-40.66M$-29.52M$-20.55M$-20.76M$-25.74M$-22.93M$-22.04M$-22.57M$-21.44M$-20.46M$-17.40M$-626.10K$-604.60K$-53.06M$-525.39K$-480.75K$-19.17M
Low Forecast$-38.56M$-38.92M$-43.27M$-40.02M$-37.05M$-36.97M$-40.66M$-29.52M$-20.55M$-20.76M$-25.74M$-22.93M$-22.06M$-22.64M$-21.44M$-20.46M$-17.40M$-626.10K$-604.60K$-79.59M$-525.39K$-480.75K$-28.76M
Surprise %------------21.59%4.89%1.82%0.20%-0.09%5.43%-14.14%0.09%-19.75%-7.53%0.28%

1 analysts predict CMAX's average Quarter EBITDA for Mar 23 to be $-20.46M, with a high of $-20.46M and a low of $-20.46M. This is -1440.61% lower than CareMax's previous annual EBITDA (Dec 22) of $1.53M.

CareMax Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts11111111111131111111111
Net Income------------$-465.77M$-103.12M$-32.38M$-82.08M$10.43M$-22.05M$-9.38M$-16.80M$2.24M$-2.85M$-7.36M
Avg Forecast$-3.57M$-5.03M$-6.75M$-7.79M$-14.99M$-17.71M$-21.77M$-15.50M$-27.31M$-30.32M$-31.44M$-31.46M$-18.00M$-12.50M$-9.66M$-14.10M$-7.47M$-7.27M$-6.83M$-113.38M$-7.79M$-9.42M$-29.82M
High Forecast$-3.57M$-5.03M$-6.75M$-7.79M$-14.99M$-17.71M$-21.77M$-15.50M$-27.31M$-30.32M$-31.44M$-31.46M$-18.00M$-12.50M$-9.66M$-14.10M$-7.47M$-7.27M$-6.83M$-90.70M$-7.79M$-9.42M$-23.86M
Low Forecast$-3.57M$-5.03M$-6.75M$-7.79M$-14.99M$-17.71M$-21.77M$-15.50M$-27.31M$-30.32M$-31.44M$-31.46M$-18.00M$-12.50M$-9.66M$-14.10M$-7.47M$-7.27M$-6.83M$-136.06M$-7.79M$-9.42M$-35.79M
Surprise %------------25.87%8.25%3.35%5.82%-1.40%3.03%1.37%0.15%-0.29%0.30%0.25%

CareMax's average Quarter net income forecast for Mar 23 is $-14.10M, with a range of $-14.10M to $-14.10M. CMAX's average Quarter net income forecast represents a -235.11% decrease compared to the company's last Quarter net income of $10.43M (Dec 22).

CareMax SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts11111111111131111111111
SG&A------------$20.34M$22.78M$24.12M$27.71M$20.90M$24.04M$20.36M$22.28M$18.93M$14.86M$9.66M
Avg Forecast$57.20M$57.73M$64.18M$59.36M$54.95M$54.84M$60.31M$43.78M$30.48M$30.79M$38.18M$34.01M$32.71M$33.53M$31.80M$30.34M$25.81M$45.60M$44.03M$42.05M$38.27M$35.01M$39.11M
High Forecast$57.20M$57.73M$64.18M$59.36M$54.95M$54.84M$60.31M$43.78M$30.48M$30.79M$38.18M$34.01M$32.72M$33.58M$31.80M$30.34M$25.81M$45.60M$44.03M$42.05M$38.27M$35.01M$46.93M
Low Forecast$57.20M$57.73M$64.18M$59.36M$54.95M$54.84M$60.31M$43.78M$30.48M$30.79M$38.18M$34.01M$32.69M$33.48M$31.80M$30.34M$25.81M$45.60M$44.03M$42.05M$38.27M$35.01M$31.29M
Surprise %------------0.62%0.68%0.76%0.91%0.81%0.53%0.46%0.53%0.49%0.42%0.25%

CareMax's average Quarter SG&A projection for Mar 24 is $34.01M, based on 1 Wall Street analysts, with a range of $34.01M to $34.01M. The forecast indicates a 67.18% rise compared to CMAX last annual SG&A of $20.34M (Dec 23).

CareMax EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts11111111111131111111111
EPS------------$-0.12$-0.92$-0.29$-0.74$0.10$-0.25$-0.11$-0.19$0.03$-0.03$-0.26
Avg Forecast$-0.94$-1.32$-1.77$-2.05$-3.94$-4.65$-5.72$-4.07$-7.17$-7.96$-8.26$-8.26$-4.73$-3.28$-2.54$-3.70$-1.96$-1.91$-1.79$-0.42$-2.05$-2.48$-1.20
High Forecast$-0.94$-1.32$-1.77$-2.05$-3.94$-4.65$-5.72$-4.07$-7.17$-7.96$-8.26$-8.26$-4.73$-3.28$-2.54$-3.70$-1.96$-1.91$-1.79$-0.42$-2.05$-2.48$-1.20
Low Forecast$-0.94$-1.32$-1.77$-2.05$-3.94$-4.65$-5.72$-4.07$-7.17$-7.96$-8.26$-8.26$-4.73$-3.28$-2.54$-3.70$-1.96$-1.91$-1.79$-0.42$-2.05$-2.48$-1.20
Surprise %------------0.03%0.28%0.11%0.20%-0.05%0.13%0.06%0.46%-0.01%0.01%0.22%

According to 1 Wall Street analysts, CareMax's projected average Quarter EPS for Mar 23 is $-3.70, with a low estimate of $-3.70 and a high estimate of $-3.70. This represents a -3802.41% decrease compared to CMAX previous annual EPS of $0.10 (Dec 22).

CareMax Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CMAXCareMax$0.42$2.20423.81%Hold
EVHEvolent Health$10.87$33.00203.59%Buy
FORAForian$2.04$4.50120.59%Buy
CERTCertara$11.40$15.0031.58%Buy
HCATHealth Catalyst$7.65$9.6726.41%Buy
HQYHealthEquity$91.09$108.3318.93%Buy
PRVAPrivia Health Group$20.79$23.0010.63%Buy
HSTMHealthStream$31.97$29.00-9.29%Buy

CMAX Forecast FAQ


Is CareMax a good buy?

No, according to 2 Wall Street analysts, CareMax (CMAX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of CMAX's total ratings.

What is CMAX's price target?

CareMax (CMAX) average price target is $2.2 with a range of $2.2 to $2.2, implying a 1293.90% from its last price of $0.158. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will CareMax stock go up soon?

According to Wall Street analysts' prediction for CMAX stock, the company can go up by 1293.90% (from the last price of $0.158 to the average price target of $2.2), up by 1293.90% based on the highest stock price target, and up by 1293.90% based on the lowest stock price target.

Can CareMax stock reach $0?

CMAX's average twelve months analyst stock price target of $2.2 supports the claim that CareMax can reach $0 in the near future.

What are CareMax's analysts' financial forecasts?

CareMax's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.24B (high $1.24B, low $1.24B), average EBITDA is $-144M (high $-144M, low $-144M), average net income is $-69.967M (high $-69.967M, low $-69.967M), average SG&A $213.88M (high $213.88M, low $213.88M), and average EPS is $-18.376 (high $-18.376, low $-18.376). CMAX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.38B (high $1.38B, low $1.38B), average EBITDA is $-161M (high $-161M, low $-161M), average net income is $-23.154M (high $-23.154M, low $-23.154M), average SG&A $238.47M (high $238.47M, low $238.47M), and average EPS is $-6.081 (high $-6.081, low $-6.081).

Did the CMAX's actual financial results beat the analysts' financial forecasts?

Based on CareMax's last annual report (Dec 2023), the company's revenue was $751.1M, beating the average analysts forecast of $744.52M by 0.88%. Apple's EBITDA was $-711M, beating the average prediction of $-86.555M by 721.28%. The company's net income was $-683M, beating the average estimation of $-54.254M by 1159.53%. Apple's SG&A was $94.96M, missing the average forecast of $128.38M by -26.03%. Lastly, the company's EPS was $-0.18, missing the average prediction of $-14.249 by -98.74%. In terms of the last quarterly report (Dec 2023), CareMax's revenue was $151.84M, missing the average analysts' forecast of $189.69M by -19.96%. The company's EBITDA was $-476M, beating the average prediction of $-22.053M by 2059.05%. CareMax's net income was $-466M, beating the average estimation of $-18.001M by 2487.49%. The company's SG&A was $20.34M, missing the average forecast of $32.71M by -37.81%. Lastly, the company's EPS was $-0.12, missing the average prediction of $-4.728 by -97.46%